rythropoietin (EPO) is essential for the maintenance of red blood cells in humans as well as in various animal models (1) , reviewed in ref. 2 . In humans, the kidney is the primary source of EPO synthesis, whereas other organs such as the liver and brain produce small but significant amounts in adults (3) (4) (5) (6) . Deficits in EPO production result in anemia in humans and in animal models. In humans, the most prevalent form of anemia is associated with kidney failure (7) . At present, the only treatment for this form of anemia is administration of recombinant EPO via subcutaneous or intravenous injection (8) (9) (10) . The use of recombinant EPO has significantly improved the quality of life of these patients; however, this treatment requires repeated administration of recombinant protein, which is both inconvenient and expensive.
EPO induces its biological effects after binding to a cellsurface receptor (EPOR). Binding of EPO to EPOR results in dimerization of these receptors, as is the case for many other growth factor and cytokine receptors (11, 12) . Apparently dimerization of EPOR is all that is required to trigger the biological responses associated with EPO. A constitutively active (hormone-independent) EPOR was first isolated after retroviral transduction (13) . The activation of this receptor mapped to an arginine-to-cysteine mutation at position 129 in the human EPOR. The mutant receptor forms disulfide-linked homodimers in the absence of EPO (14) . After this example, more constitutively active EPORs have been created by introducing a cysteine residue in parts of the putative EPOR dimerization interphase (15, 16) . These mutant receptors, when introduced into growth factor-dependent BAF3 cells, converted them into growth factor-independent cells. Similarly, a bivalent monoclonal antibody directed toward the extracellular domain of the EPOR promotes dimerization of EPOR and mimics EPO activities (17) . Moreover, recently a 20-aa peptide, EPO mimetic peptide-1 (EMP-1), has been shown to dimerize the EPOR in solution as well as on the cell surface (18, 19) . This peptide exhibits EPO-like activities both in vitro and in vivo (18) .
The crystal structures of EPO͞EPOR and EMP-1͞EPOR complexes have been solved and reveal a different configuration of the EPOR dimer in each of the complexes (19, 20) . On the basis of the three-dimensional structure of EPOR observed in these crystals, the mutations described above are in a region of the exoplasmic domain that is too far away for disulfide bond formation to occur between the two EPOR molecules. Therefore, it is unlikely that the covalently held EPOR dimers induced by mutations in the exoplasmic domain (as described above) will have a configuration similar to that of EPO-or EMP-1-induced EPOR dimers. A similar conclusion may be drawn for the monoclonal antibody-induced EPOR dimers. All these data suggest that, although the dimerization of the EPOR is important, the conformation of EPOR in the dimer complex is quite flexible. This also suggests that other molecules capable of dimerizing the EPOR may be able to act as EPO mimetics as well.
We are interested in developing small-molecule EPO mimetics for the treatment of anemia. On the basis of the characteristics of EPOR-dimerizing entities described above, it appears that such a molecule must have functional groups capable of interacting with at least two receptor chains. One possible way to obtain such a molecule is to first identify a compound that can interact with one chain of the EPOR and then ligate it in such a way that it can now interact with both chains of the receptor. In this paper, we report on the identification of such a molecule, which we initially identified as an EPOR antagonist. This molecule, when presented as an oligomer, is converted into an EPOR agonist, recapitulating some of the biological activities associated with EPO.
Materials and Methods
Synthesis of Compounds and EMP-1. Compound 1 was synthesized by using Starburst polyamidoamino-octa-4-hydroxymethylbenzamide (2) as a soluble support, as shown in Fig. 1 . To a stirring solution of support 2 (0.05 mmol, 105 mg) (21) and FmocLys(Boc)-OH (0.8 mmol, 364 mg, 2 eq per handle) in 3 ml of N,N-dimethylformamide (DMF) was added catalytic 4-dimeth-ylaminopyridine (3-5 mg), followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.8 mmol, 154 mg). The reaction was stirred overnight at ambient temperature. Dendrimer 3 was isolated by size exclusion chromatography (SEC) on Sephadex LH-20 (Amersham Pharmacia) eluting with DMF, followed by SEC on Bio-Rad Biobeads S-X3 eluting with CH 2 Cl 2 . Removal of solvent in vacuo afforded 204 mg of 3 as a beige solid. Compound 3 (0.016 mmol, 100 mg) was treated with 3 ml of 30% piperidine in DMF for 15 min and isolated by SEC on Sephadex LH-20. The resulting octa-amine was dried in vacuo, and residue was dissolved in 3 ml of DMF containing 3-(4-biphenylbenzoyl)propionic acid (0.3 mmol, 76 mg, 2.3 eq) and 1-hydroxybenzotrazole hydrate (0.3 mmol, 41 mg). To the solution was added diisopropylcarbodiimide (0.3 mmol, 54 L). The mixture was allowed to stand overnight, and the product was isolated by SEC on Biobeads S-X3 eluting with CH 2 Cl 2 . Removal of solvent afforded 114 mg of dendrimer 4 as a beige solid. Dendrimer 4 (84 mg) and 3-chloro-4-tolylhydrazinium chloride (1.5 mmol, 290 mg) were dissolved in 3 ml of glacial acetic acid containing zinc chloride (1.5 mmol, 204 mg) and anisole (0.6 mmol, 60 mg, 60 L), and the slurry was heated overnight at 70°C. The solvent was removed in vacuo, and the residue was dissolved in DMF and purified by SEC on Sephadex LH-20. Removal of solvent afforded 68 mg of 5 as a tan solid. 1 H NMR of 5 revealed the removal of the Boc-protecting group during the reaction. Dendrimer 5 (40 mg) was taken up in 2 ml of 9:1 MeOH͞Et 3 N and heated at 50°C for 22 hr. The mixture was rotary evaporated to a tan film, which was taken up in MeCN. The insoluble dendrimer was filtered, and the light-colored filtrate was rotary evaporated to afford 17 mg of methyl esters 1 and 1b as the major products, in addition to the corresponding cyclized lactams. Separation of the two regioisomers by reverse-phase chromatography (C-8, H 2 O͞MeCN gradient containing 0.15% triflu- 2H) . Dried powders were stored at ambient temperatures and used for preparation of stock solutions in 100% DMSO. Stock solutions prepared in this way were stored at Ϫ20°C until use and were used within a few months, during which no loss of activity was observed as determined by activities of these compounds in the EPORbinding and luciferase-reporter gene assays described here. EMP-1, GGTYcyclo(CHFGPLTWVC)KPQGG-amide, was prepared by the solid-phase method (22) (23, 24) were maintained in the above-mentioned media supplemented with hIL-3 (5 ng͞ml).
Plasmids. pET15b͞hEPOR-ECD expresses the extracellular domain of the human EPOR in Escherichia coli, and RcCMV͞ EPOR expresses human EPOR in mammalian cells and will be described elsewhere (H.M., unpublished data). pAH4-LUC contains six copies of the signal transducer and activator of transcription (STAT)-binding site from the interferon regulatory factor 1 gene cloned upstream of the herpes simplex virusthymidine kinase minimal promoter and the luciferase gene (25) . A gene cassette conferring resistance to the antibiotic Zeocine (Invitrogen) was introduced at a SalI site in the pAH4LUC to yield pAH4LUCZeo.
Expression and Purification of EPO-Binding Protein in E. coli. E. coli strain BL21 DE3 (Novagen) containing pET15b͞hEPOR-ECD was used for expression of the extracellular domain of the human EPOR. The resulting recombinant protein was processed to yield the recombinant EPO-binding protein (rEBP) as described previously (26) . An EPO-dependent luciferase assay was used to further characterize the rEBP. The purified rEBP inhibited EPO-induced luciferase activity in this assay with an IC 50 of 5-10 nM (S.Q. and R.R., unpublished data). 0.5% BSA͞0.05% Tween 20͞0.01% sodium azide͞5% DMSO ϩ͞Ϫ compounds. To set up these assays, each compound was diluted into the assay buffer (from the stocks that have been prepared in 100% DMSO) to yield the appropriate compound concentration and added to each well of a 96-well plate. These reactions were incubated at 4°C for 16-20 hr to allow equilibrium binding, and unbound 125 I-EPO was removed by five rapid washes with cold 1ϫ PBS containing 0.5% BSA. Bound radioactivity was counted, after addition of 100 l of Microscint (Packard)͞well, in a Topcount scintillation counter (Packard). Under these conditions, unlabeled EPO inhibited binding of 125 I-EPO with an IC 50 of Ϸ5 nM.
EPOR Dimerization Assay. A detailed description of this assay will be published elsewhere (D.B. and S.Q., unpublished work). Briefly, rEBP containing a protein kinase A substrate site was produced in E. coli as described above. This protein was radiolabeled by using protein kinase A and 33 P-␥ATP to high specific activity. The soluble 33 P-rEBP was allowed to interact with the plate-bound rEBP as described for the receptor-binding assay. Each reaction was performed in a 100 l volume containing 1-to 2-nM-labeled rEBP in 50 mM Hepes (pH 7.2)͞5 mM Mg 2 Cl͞5 mM Ca 2 Cl͞0.05% sodium azide͞1% BSA͞5% DMSO͞ϩ͞ Ϫcompounds) in 96-well microtiter plates in the presence or absence of 250 ng͞well immobilized rEBP. After incubation for 16-20 hr in the presence or absence of compounds, plates were washed, and the amount of radioactivity was determined as described in the EPOR-binding assay. Hematopoietic Colony Assays. Colony assays were set up by using human CD34 ϩ mononuclear cells isolated from healthy donors. One thousand to two thousand cells were mixed with 1 ml of methylcellulose culture medium containing FBS (StemCell Technologies, Vancouver), 0.4% DMSO, a mixture of growth factors containing granulocyte-macrophage colony stimulating factor (GM-CSF), IL-3, granulocyte colony stimulating factor (G-CSF), and stem cell factor (HC-4535-StemCell Technologies, Vancouver), and EPO (Epoetin Alfa, Amgen Biologicals) or compounds. After thorough mixing, the suspension was plated in 35-mm gridded plates (Nunc) and incubated at 37°C in a humidity controlled CO 2 incubator. Colony-forming units (CFU)-erythroid containing Ͼ50 hemoglobinized cells and myeloid colonies (CFU-GM) containing Ͼ50 cells were counted on day 12-14. Mixed colonies, containing both erythroid and myeloid cells, were counted on day 14-16. All assays were performed at Poietic Technologies, Gaithersburg, MD.
Results and Discussion

Compound 5, an Antagonist of EPO-Binding to EPOR, also Induces
Dimerization of the EPOR. To test the hypothesis that a multimeric form of an EPOR antagonist can function as an EPO mimetic to dimerize and activate the EPOR, we screened the in-house chemical collection for inhibitors of EPO binding to the EPOR using the extracellular domain of the human EPOR as rEBP. Inhibition of 125 I-EPO binding to rEBP. Dose-response curve for inhibition of 125 I-EPO binding by compounds 1, 2, and 5. Competition binding experiments were performed in a volume of 50 l containing 5 nM 125 I-EPO in the presence or absence of compounds and allowed to proceed for at least 16 hr at 4°C, as described in Materials and Methods. Nonspecific EPO binding was determined by performing the experiments in the presence of 1 M unlabeled EPO and was found to be less than 10% (under these conditions, we routinely obtained a total of 3,000 -5,000 counts per minute (cpm)͞well with no compound and 200 -400 cpm͞well in the presence of 1 M cold EPO). The data are expressed as a percentage of the EPO (specific cpm) bound in the presence of 5% DMSO but in the absence of any compound (which is considered as 100%). Each data point was analyzed in triplicate and is a mean (ϩ͞Ϫ SEM) of three independent experiments. 4.4 ϩ͞Ϫ 1.9 M (Fig. 2) . Compound 2, the unconjugated dendrimer used to crosslink compound 1, did not affect binding of 125 I-EPO to the rEBP in this assay. The ability of compound 5 to inhibit binding of 125 I-EPO to the rEBP suggests that compound 1, even when attached to an inactive central core, is able to interact with rEBP.
This screening resulted in identification of N-3-[2-(4-biphenyl)-
The biological activation of EPOR requires dimerization of EPOR on binding of EPO to two independent chains of EPOR. Thus, one of several ways for a small molecule to activate the EPOR is to induce dimerization of the EPOR. To determine whether compound 1 or 5 can dimerize EPOR in solution, we tested these compounds in an EPOR dimerization assay. This assay examined the interaction of a radiolabeled form of rEBP ( 33 P-rEBP) in solution with a plate-immobilized rEBP. In the absence of any dimerizing agent in the assay, the labeled receptor fails to attach to the plate and is easily washed off during the washing step (at the end of the assay). However, in the presence of a compound that can interact with at least two chains of EPOR, the radiolabeled chain would be expected to remain bound to the plate, resulting in increased retention of 33 P-rEBP in the assay. EMP-1, a 20-aa peptide, which has been shown to induce dimerization of this form of EPOR in solution (18) , produces a dose-dependent increase in the retention of 33 P-rEBP (Fig. 3) . When tested in this assay, compound 5 produced a dose-dependent increase (EC 50 15.9 ϩ͞Ϫ 3.3 M) in retention of 33 P-rEBP, whereas compounds 1 and 2 both failed to produce any such increases (Fig. 3) . These data suggest that even though compounds 1 and 5 both compete for the binding of EPO to the rEBP, only compound 5 is able to interact with more than one chain of EPOR.
Compound 5 Induces Cellular Transcription and Proliferation in Cells
Expressing EPOR. Binding of EPO to its cell-surface receptors results in the activation of cellular signaling pathways, including activation of janus kinase (JAK)2 and STAT5 (27) (28) (29) . STAT5 is a transcription factor that translocates to the nucleus on activation and induces gene transcription (30) . Luciferase reporter gene constructs containing synthetic promoters with STAT-binding sites have been used as markers for the activation of STATs in cells (31) (32) (33) . To determine whether compound 5 could interact with the EPOR expressed in mammalian cells, induce receptor oligomerization as seen in vitro (Fig. 3) , and activate the JAK-STAT signaling pathway, we tested this compound on BAF3͞LUC cells. The BAF3͞LUC cells have a stably integrated luciferase gene under the control of a STAT-binding site from the interferon regulatory factor 1 gene. This STATbinding site has been shown to function in response to activation signals involving STATs 1-5 (25, (34) (35) (36) . Because BAF3 cells do not normally express EPORs, they do not manifest any biological response when treated with EPO; however, they can acquire EPO responsiveness once the EPOR is expressed ectopically (37, 38) . However, these cells do express IL-3 receptors and in response to IL-3 activate the JAK2 and STAT5 signaling pathway (39-41). As shown in Fig. 4 , treatment with IL-3 increases the luciferase activity in both BAF3͞LUC and BAF3͞LUC͞ EPOR cells, demonstrating that these cells are competent in responding to receptor-dependent activation of Stat5. As expected, EPO-dependent increases in the luciferase activity were observed in the EPO-treated BAF3͞LUC͞EPOR cells but not in EPO-treated BAF3͞LUC cells. When tested in these cells, compound 5 induced increases in the luciferase activity only in the BAF3͞LUC͞hEPOR cells with an EC 50 of 1.25 M. No such increases were observed in BAF3͞LUC cells (Fig. 4) . Moreover, neither compound 1 nor compound 2 induced any increases in the luciferase activity in either of these two cell lines. The decrease in the luciferase activity observed at higher concentrations of compound 5 may be caused by toxicity or by the engagement of EPOR in a 1:1 (EPOR͞compound) complex, thus preventing the formation of EPOR dimers needed for the activation of the JAK-STAT pathway. Formation of this 1:1 receptor͞ligand complex at high ligand concentration has been Dimerization of soluble EPOR. 33 P-rEBP was incubated with or without plate-immobilized rEBP (as in Fig. 2 ), in the absence or presence of compounds 1, 2, or 5 or EMP-1 for 16 hr at 4°C, as described in Materials and Methods. Data represent specific cpm (cpm with plate-immobilized EPOR minus cpm without plate-immobilized EPOR) observed with each of the compounds. Data are a mean of two experiments (ϩ͞Ϫ SEM) performed in triplicate. Under these conditions, mean cpm observed in wells with no compounds were 147 ϩ͞Ϫ 25). shown to inhibit the activation of growth hormone and EPORs by their respective ligands (17, 42) .
BAF3 cells are known to proliferate in the presence of IL-3 and a number of other cytokines, including EPO, provided that the receptors for these cytokines are expressed in these cells. The increased proliferation results in increased incorporation of nucleotides, such as a thymidine, into DNA, which can be measured by using 3 H-thymidine. Much like what was observed for the luciferase reporter gene activation, IL-3 induced increases in the 3 H-thymidine incorporation in both BAF3 and BAF3͞hEPOR cells, but EPO induced these increases in BAF3͞ hEPOR cells only (Fig. 5) . When tested in these cells, compound 5 induced 3 H-thymidine incorporation in BAF3͞hEPOR cells but not in parental BAF3 cells, similar to the response to EPO. However, compound 2 failed to show any activity in the assay (because of lack of activity in the EPOR dimerization and luciferase reporter gene assay, compound 1 was not evaluated in this or any subsequent assays), and again compound 5 showed a decreased activity at higher concentrations, which could be caused by nonspecific cellular toxicity or unproductive engagement of receptors (as suggested above). BAF3 cells require the presence of a cytokine such as IL-3 even for survival in cell culture, thus making it difficult to distinguish between these two possibilities. However, this phenomenon is not limited to BAF3 cells, because we have observed similar inhibition at high concentrations in DA3͞hEPOR cells, another murine cell line, as well as in F36E and TF-1 cells, two cell lines of human origin known to respond to EPO via the endogenous EPOR (23, 24) . Moreover, we have observed a compound 5-dependent inhibition of IL-3-induced thymidine incorporation in BAF3 cells lacking the EPOR (S.Q. and R.R., unpublished observation), which supports the notion that the toxicity of compound 5 is nonspecific and independent of the EPOR. More experiments will be needed to sort out this phenomenon. Regardless of the complexity in the interpretation of the data at higher doses of compound 5, these data still demonstrate that compound 5 interacts with the EPOR expressed on the cell surface, resulting in induction of EPO-like activities.
Compound 5 Induces Differentiation of Human Progenitor Cells into
Cells of Erythrocytic Lineage. EPO induces differentiation of hematopoietic progenitor cells into mature erythrocytes in vivo. However, in tissue culture conditions, only a part of this process is recapitulated. Progenitor cells isolated from peripheral blood or bone marrow when cultured in vitro in semisolid media can grow into morphologically distinct colonies (each colony being a product of single progenitor cell), depending on which growth factor is present in the media. For example, it is well known that EPO, in the presence of stem cell factor and IL-3, induces the formation of colonies known as CFU-E (Colony Forming UnitErythroid), which are easily identified microscopically because of the hemoglobinization of cells in the colony. Cells isolated from human peripheral blood by using an anti-CD34 antibody (CD34 ϩ cells) are more advanced progenitors capable of differentiation into erythrocytes in the presence of EPO and into granulocytes and macrophages in the presence of G-CSF and GM-CSF (43, 44) . We used these cells to examine the ability of compound 5 to replace EPO in promoting differentiation of these progenitor cells into erythroid colonies in vitro. Cells plated in the presence of growth factors (stem cell factor, IL-3, GM-CSF, and G-CSF) alone did not develop into erythroid colonies, even though these were able to form colonies of GM progenitor cells (CFU-GM) indicating the viability of these isolated cells (Table 1) . However, addition of EPO to the mixture of growth factors induced formation of erythroid colonies in a dose-dependent manner. Under the same conditions, compound 5 also induced erythroid colonies, whereas compound 2 did not 
Human CD34 ϩ progenitor cells (1.5 ϫ 10 3 ͞plate) were plated in semisolid media to allow growth of erythroid colonies and GM colonies. Colonies of each type were counted after 12-15 days of seeding under each condition. Data are mean (SEM) of two independent experiments, where each determination was performed in triplicate.
induce erythroid colonies and did not inhibit the formation of GM colonies. Moreover, no morphological differences could be observed between the EPO-induced erythroid colonies or the compound-induced erythroid colonies. These data confirm that compound 5 is an EPO mimetic capable of inducing the proliferation and differentiation of human erythroid progenitor cells.
In summary, we have reported on the identification and characterization of an EPOR antagonist, which when presented in a multivalent configuration induced biological responses similar to what is normally observed with EPO. Although the potency of the activities observed with this compound is only a fraction of what is expected of EPO, it does validate the concept that the EPOR, and by extension most cytokine receptors, can be ligated together in an active conformation by a nonpeptidyl molecule. The only requirement is that the small molecule must be able to interact with both chains of the receptor. This paper also lays out a basic strategy for identifying cytokine mimetics by converting an antagonist into an agonist.
